What’s the Controversy About Aduhelm?
“Behold the deluge,” begins the February 18, 2022 article on the ALZFORUM titled, “On Aduhelm, Medicare Agency Gets Pressure From all Sides”. CMS received 9,956 public comments during its open comment period ending February 10, 2022 to hear from the public about its draft (temporary) decision to approve coverage for Aduhelm for people with Alzheimer’s only if they were enrolled in approved clinical trials. Organizations such as the Alzheimer’s Association and UsAgainstAlzheimer’s, both strongly in support of making Biogen’s drug Aduhelm (also […]